News Archives - Bay Area Lyme Foundation

Science Translational Medicine Study Funded by the Bay Area Lyme Foundation Identifies FDA-approved Piperacillin as More Effective, Targeted Treatment for Lyme Disease

By Bay Area Lyme Foundation

FOR IMMEDIATE RELEASE

Science Translational Medicine Study Funded by the Bay Area Lyme Foundation Identifies FDA-approved Piperacillin as More Effective, Targeted Treatment for Lyme Disease

An additional Science Translational Medicine study also funded by Bay Area Lyme Foundation uncovers how lingering bacterial cell wall molecules may contribute to chronic Lyme symptoms

PORTOLA VALLEY, Calif. April 23, 2025 – Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the US, announces two pre-clinical studies published in the peer-reviewed journal Science Translational Medicine. The studies demonstrate promising implications for improved Lyme disease treatment and understanding of chronic Lyme through peptidoglycan, a molecule found in the cell wall of the bacterium, Borrelia burgdorferi (Bb), which causes Lyme disease. The first study finds piperacillin, an FDA-approved treatment for pneumonia that inhibits peptidoglycan production, may be a more effective treatment for Lyme disease than the current “gold standard” treatment, doxycycline, which is not effective for up to 20% of patients. The second study uncovers how lingering peptidoglycan builds up in the joint fluid and liver, contributing to chronic Lyme symptoms, which affect over 20% of patients treated for Lyme disease.

“Piperacillin may be a game-changer for improving Lyme disease treatment, which is currently a challenge for researchers and physicians. Furthermore, our new mechanistic understanding of how piperacillin affects peptidoglycan synthesis is unexpectedly informing our development of a biomarker-based approach to diagnose acute Lyme disease,” said Brandon Jutras, PhD, associate professor of Microbiology-Immunology at Northwestern University Feinberg School of Medicine, and a Bay Area Lyme Foundation 2021 Emerging Leader Award winner. “Our second study explores the role of peptidoglycan in chronic Lyme symptoms; peptidoglycan influences an inflammatory and chronic illness response for weeks or even months after infection, adding to the growing evidence that remnants of bacteria and viruses can stick around and keep affecting the body, similar to the occurrence of Long COVID in some patients.”

Nancy Haney’s Death: A Tragic Story of Misdiagnosis, Delayed Diagnosis, and Medical Failure

By Bay Area Lyme Foundation

Bay Area Lyme Spotlights Series

“If you have someone who’s sick and you are treating them and they’re not getting better, then either the treatment is wrong or the diagnosis is wrong.”

– David Haney, PhD

Nancy Haney was a highly respected pediatric physical therapist who developed serious health problems that were misdiagnosed over many years, leading to delays in treatment. After exhaustive efforts, it was determined that Nancy had developed an autoimmune condition—likely triggered by Lyme disease—that resulted in debilitating symptoms and complications, including a long-lasting case of shingles, which eventually led to a fatal hemorrhagic stroke. David Haney, Nancy’s husband, recounts his tireless pursuit to find Nancy appropriate care and treatment. Despite his efforts, the mainstream medical system repeatedly failed to correctly diagnose and treat Nancy’s underlying conditions, which led to a tragic and preventable outcome.

David’s story is a call to action for greater awareness, more comprehensive training for doctors, and a fundamental shift in the medical community’s approach to complex, multifaceted infection-associated chronic conditions. Nancy’s case highlights the critical need for improved awareness, diagnostic tools, and treatment approaches for complex cases involving Lyme and tick-borne diseases. Only then can we hope to prevent other families from enduring the same treatment failures as the Haney family.

Connection and Collaboration Bringing Hope: Understanding the Immune System’s Role in Post-Treatment Lyme Disease

By Bay Area Lyme Foundation

Bay Area Lyme Spotlights Series

“Philanthropy is mission-critical to advance the field of Lyme disease research.”

– Bill Robinson, MD, PhD

In this conversation, we talk with Bill Robinson, MD, PhD, the James W. Raitt professor of medicine and division chief, division of immunology and rheumatology at Stanford University, about how his work is helping us understand the immune system’s response to a Lyme infection. A long-term collaborator and grant recipient of Bay Area Lyme Foundation, Dr. Robinson reflects on his history with our organization, the plight of Lyme patients, the paucity of government funding for investigations into the disease, where Lyme disease research is now, and where he thinks it’s headed in the next 5-10 years.

Dr. Neil Nathan: When You’re Not Getting Better. Best-selling Author and Chronic Illness Expert has Answers.

By Bay Area Lyme Foundation

Bay Area Lyme Quick Bites series

“If you have Lyme disease and your treatment is stalled out or not moving or you’re not progressing the way you should, please check for mold. It’s almost certain that’s what you need to be working on next.”

– Neil Nathan, MD

Our Ticktective host, Dana Parish, interviews Dr. Neil Nathan, renowned physician and best-selling author. Dr. Nathan specializes in treating chronic illnesses, particularly those related to environmental toxins, vector-borne infections, and complex systemic disorders. With decades of experience in clinical practice, he focuses on understanding the impact of toxins on health and is dedicated to helping patients recover from illnesses that conventional medicine often struggles to address. His bestselling book, Toxic: Heal Your Body from Mold Toxicity, Lyme Disease, Multiple Chemical Sensitivities, and Other Chronic Environmental Illnesses, provides a comprehensive guide to recognizing, diagnosing, and treating various chronic conditions linked to environmental factors.

Click here to watch or listen now.

Award-Winning Short-Form YouTube Series ‘Girl at a Bar’ Depicts Challenges of Living with Chronic Lyme

By Bay Area Lyme Foundation

Bay Area Lyme Spotlights Series

“I hope people with Lyme can see themselves on screen and they resonate with it.”

– Tracy Mulholland

We sat down with Tracy Mulholland, actress, writer, producer, and Lyme patient, who wrote, produced, and stars in the award-winning short-form series Girl at a Bar, made possible by a grant from Bay Area Lyme Foundation. The short-form series, now available on YouTube, aims to provide an entertaining, accessible narrative to raise awareness about Lyme. Tracy hopes it will resonate with those living with chronic conditions and spark more conversations and content about these experiences. We discuss Tracy’s personal story as the inspiration behind the show and how the series explores challenges relevant not only to people navigating chronic illness but also to life in general. Conversation topics include:

How the show is inspired by the creator’s own experiences with Lyme disease, including the social isolation and impacts on relationships that can occur during chronic illness.
An exploration around themes of identity, vulnerability, and empathy, drawing parallels to other chronic and invisible illnesses beyond Lyme.
In addition to the short-form series, Tracy is launching a related spin-off podcast series where others are challenged to push their comfort zones.
Each episode aims to humanize the Lyme experience, foster greater understanding, and inspire more diverse storytelling about chronic illnesses in media and entertainment.

Pathogens and Persistence: The Chronic Disease Drivers

By Bay Area Lyme Foundation

BAL “Quick Bites” Series

“I’ve always said that the FDA has been captured by the pharmaceutical industry. They don’t have our best interests at heart. You shouldn’t be funded by the people you’re supposed to be regulating.”

– Steven Phillips, MD

Ticktective host, Dana Parish, talks with her longtime collaborator and co-author of Chronic, Dr. Steven Phillips, a Yale-trained internal medicine doctor who specializes in treating patients with complex, chronic illnesses, often driven by underlying infections like Lyme, Bartonella, Babesia, and now, COVID. In this podcast episode, Phillips discusses the importance of getting to the root cause of mystery autoimmune illnesses, rather than just suppressing symptoms. He states that many chronic infections can drive autoimmune conditions, including Lyme disease, and that Lyme tests are often inaccurate, with a sensitivity of around 50%. Phillips discusses how he recommends treating suspected tick bites to prevent the development of chronic Lyme disease and his use of a multi-antibiotic approach and pulsed antibiotic therapy to target persistent infections. He also discusses his experiences treating COVID-19, using a multi-modal approach including doxycycline, Paxlovid, Metformin, and other drugs and supplements, and the reactivation of infections like Bartonella in Long COVID patients. They also discuss how the chemical and pharmaceutical industries’ interests do not necessarily align with patients trying to get well. The interview highlights Dr. Phillips’s expertise in treating complex chronic infections and his holistic, evidence-based approach to patient care.

UCSF’s New Lyme Clinical Trials Center: Addressing the Need for Evidence-Based Treatments for Lyme & TBD Patients

By Bay Area Lyme Foundation

Bay Area Lyme Happenings Series

UCSF has joined the Cohen Foundation’s nationwide Lyme Clinical Trials Network (CTN) for Lyme and tick-borne diseases. The new Lyme Clinical Trials Center (CTC) at UCSF was funded by a $1m grant from Bay Area Lyme Foundation and is led by Charles Chiu, MD, PhD, and Felicia Chow, MD, as co-principal investigators. As the West Coast ‘node’ in the network, UCSF’s new Lyme Clinical Trials Center will focus on interventional trials and diagnostic studies to improve diagnosis and treatment of Lyme disease.

In this presentation to patients with Lyme disease in Marin County just north of San Francisco, Dr. Chow explains how the CTC allows for a more diverse patient population to participate in Lyme clinical trials, which is critical for developing therapies that can help a wider range of patients. UCSF’s involvement also aims to help Bay Area Lyme raise awareness that Lyme disease is prevalent year-round in almost all California counties.

Dr. Chow discusses an upcoming trial at UCSF that will evaluate the use of transcranial direct current stimulation (tDCS) to improve cognitive symptoms in patients with chronic Lyme disease. Additionally, UCSF researchers are exploring the use of metagenomic sequencing and machine learning to develop more accurate diagnostic tests for Lyme and other tick-borne infections.

Note: This transcript of Dr. Chow’s presentation has been edited for length and clarity.

“I hope that through these clinical trials, we’ll be able to identify therapies that are helpful to patients and that, as a result, have an impact on clinically meaningful outcomes—from day-to-day function, quality of life, and all of those important measures that indicate that a treatment is successful.”

– Felicia Chow, MD

The Numbers Don’t Lie: Why the NIH Consistently Underfunds Research into Lyme Disease

By Bay Area Lyme Foundation

An In-depth Interview with Kris Newby, Author of “Bitten”

“We need to let the NIH know that we’re watching them, and we want results.”

– Kris Newby

Kris Newby, author of ‘Bitten,’ is investigating government spending on Lyme disease research, which is strongly influenced by the flawed original disease definition of Lyme disease. She summarizes the impact of the 2018 Tick-Borne Disease Working Group’s report, explains where research funding has and is currently being directed, and calls for money to be spent on better diagnostics and treatments for Lyme disease sufferers instead. Kris explores potential actions that Lyme patients can take to help direct the course of funding, such as communicating with Congress, supporting advocacy groups, and donating to research organizations.

The views and opinions expressed in this article are those of the interviewee and do not necessarily reflect the views or positions of Bay Area Lyme Foundation.

Kris Newby is watching our government, and watching quite closely. She has a lot to say about how government money is spent on a disease that, according to CDC estimates, infects almost 500,000 people annually in the US, causing untold pain, suffering, loss of livelihood, and, in extreme cases, severe mental illness, including suicidal and homicidal events.

Of course, we are talking about Lyme disease—the pariah of infection-associated chronic conditions.

Bay Area Lyme Foundation Opens Applications for 2025 Emerging Leader Award and Research Grant

By Bay Area Lyme Foundation

FOR IMMEDIATE RELEASE

Bay Area Lyme Foundation Opens Applications for 2025 Emerging Leader Award and Research Grant

In its tenth year, the annual grant encourages novel approaches to revolutionizing diagnosis and treatment of tick-borne diseases

PORTOLA VALLEY, Calif., October 31, 2024 – Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the U.S., invites innovative researchers from academia and the private sector to apply for the 2025 Emerging Leader Awards (ELA). These awards recognize those advancing novel approaches in Lyme disease diagnostics and treatments, while embodying the future of Lyme disease research leadership. This year, in its tenth anniversary, Bay Area Lyme Foundation’s ELA will present two $150,000 awards for researchers who are at the post-doctoral level through associate professor level or equivalent.

While applicants must have a defined scientific approach to advancing diagnostics and/or therapeutics for Lyme disease, the grants are open to researchers from other therapeutic areas in addition to those who have previously investigated Lyme disease. Applications will be accepted through March 7, 2025 at 11:59pm, Pacific Time. The full criteria and application for this award can be found at www.bayarealyme.org/our-research/emerging-leader-award/.

“The global impact of both acute and chronic infections has never been more apparent, and tackling an infectious disease as complex as Lyme requires innovative approaches and concerted efforts to drive progress in diagnostics and treatment,” said Wendy Adams, research grant director Bay Area Lyme Foundation. “Our goal with the Emerging Leader Award is to inspire ambitious and creative scientists to take on the challenge of advancing accurate diagnostics and effective therapeutics for various stages of tick-borne diseases.”

Understanding Infection-associated Chronic Illness: How the Immune System Responds to Persistent Infection

Distinguished Speaker Series with Michal Tal, PhD

By Bay Area Lyme Foundation

Distinguished Speaker Series Transcript

“I want to leave you with hope. I think we’re going to be unstoppable because I think that these are solvable problems. These are answerable questions. I think that there are already a lot of existing tools in immunology that just need to be brought into the fight, and we can change this.”

– Michal Caspi Tal, PhD

Michal Caspi Tal: In the chronic illness world, I think that there is something about hope with a capital ‘H’ that is precious. I think it always has to be. I want to talk a little bit about what my lab is doing, where I think we could go in the future and the hope that I have for how we move forward, how we solve this, and how we change this for those who come after us. So, I’ll tell you a little bit about some of the recent things that have come out of the lab, what the lab is working on now, and where we want to go.

New Study Shows How Borrelia burgdorferi Evades the Immune System

Recently, we published a study in collaboration with Hanna Ollila’s lab where we compared people who’ve had Lyme and have had a diagnosis of Lyme versus people who’ve never had a diagnosis of Lyme. We found a genetic difference in a sweat protein that nobody—including me—had ever thought about before. We tested it against the bacteria in our lab, and we saw that it had a huge effect; we tested it in mice, and it had a huge effect. So that’s really exciting. We had another paper that came online yesterday that is one of these last papers from my postdoctoral work over at Stanford, where we actually managed to figure out some of how Borrelia burgdorferi, the bacteria that causes Lyme, manages to evade immune clearance.

Any respectable pathogen that can establish a persistent infection needs to figure out your immune system to the point that it can evade it. The fact that it has persisted means that it was able to evade your immune clearance. And so, I got to that from a very interesting direction working on immune regulation, trying to understand these brakes on the immune response and how they impact the response to infection. The immune system has the power to kill you and obviously, nobody has any incentive for that to happen. So, there are a lot of mechanisms in place to put brakes on the immune system and reign it in. One of the huge developments in cancer over the last two decades has been reevaluating the question: can we take those brakes off? So in my postdoc, I was studying a particular checkpoint where this was turning into an exciting immuno-oncology target, and I said, ‘I want to look at how this checkpoint is used in infection.’ I realized that this checkpoint was being used to help you survive an acute infection, but created a vulnerability for pathogens to evade immune clearance and establish chronic infection much like it allows cancer cells to evade immune clearance. In an amazing collaboration with Irv Weissman, Balyn Zaro, and Jenifer Coburn we realized that the bacteria that cause Lyme disease manipulate this brake and that’s how I became fascinated with Lyme. But I also became concerned about turning off this brake in cancer patients because I was concerned about what would happen if you used this on cancer patients during an active infection. Indeed, the clinical trials on this drug were ended due to increased death from infection, and I wish it hadn’t been tested during a worldwide pandemic.